Genes2Me Pvt. Ltd. announced the launch of its CoviEasy Self-Test Rapid Antigen test kit for COVID-19 on Monday, which is simple to use and provides results in ten minutes. The company claims that this IVD product, which is supported by an AI-driven mobile app, has a high level of sensitivity and concordance of more than 98 percent accuracy.
CoviEasy has passed stringent quality checks at an ICMR-approved Validation center, according to the company's press release, and has also received approval from CDSCO India. Furthermore, the CoviEasy test can be completed quickly by following the simple instructions provided on the Mobile App (which is available on both Android and iOS platforms), which results in Automated Reporting of test results from the Mobile App itself.
"Now that many of us are opting for "At-home" test kits as our first line of defense against COVID, "Accuracy" becomes non-negotiable/most important factor," said Mr. Neeraj Gupta, the Founder and CEO of Genes2Me Pvt. Ltd. in response to the product's launch. We recognized the pressing need and developed a test kit that is more than 98% accurate.
Our Covieasy kit combines the reliability of RTPCR with the convenience of an "at-home" self-test kit. We intend to assist society by providing India's most accurate kit and meeting the demand with our advanced manufacturing unit."
Genes2Me Pvt. Ltd., established in 2016, has grown to become one of India's leading IVD kit manufacturers and molecular diagnostics companies. Genes2Me has a state-of-the-art IVD kit manufacturing facility and has worked tirelessly for many years to provide people with high-quality IVD kits and point-of-care solutions. It offers a variety of high-quality COVID-19 IVD solutions, including Real-time PCR Kits, RNA Extraction Kits, Rapid Tests, Next-Generation Sequencing (NGS) Kits, and Multiplexed Genotyping assays. These IVD kits have shown accuracy, sensitivity, and specificity, as well as the ability to deliver results quickly.